FDA grants Roche's Perjeta regimen Priority Review for use before surgery in HER2-positive early-stage breast cancer
Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) for the use of a Perjeta (pertuzumab) regimen before surgery (neoadjuvant treatment) in people with HER2-positive early-stage breast cancer.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Grants | HER2 | Neoadjuvant Therapy | Pharmaceuticals